

Naveen Garg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2548371/publications.pdf>

Version: 2024-02-01

62
papers

1,878
citations

471509

17
h-index

276875

41
g-index

63
all docs

63
docs citations

63
times ranked

3118
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 647-656.	1.4	2
2	The Role of Home-Based Exercise in Maintaining Skeletal Muscle During Preoperative Pancreatic Cancer Treatment. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542098661.	2.0	20
3	Frequency of Sarcopenia, Sarcopenic Obesity, and Changes in Physical Function in Surgical Oncology Patients Referred for Prehabilitation. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542110001.	2.0	9
4	DropConnect is effective in modeling uncertainty of Bayesian deep networks. <i>Scientific Reports</i> , 2021, 11, 5458.	3.3	43
5	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. <i>Leukemia</i> , 2021, 35, 3421-3429.	7.2	22
6	Thrombosis and bleeding outcomes in the treatment of cerebral venous thrombosis in cancer. <i>Thrombosis Journal</i> , 2021, 19, 37.	2.1	2
7	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2021, 7, 1213.	7.1	53
8	Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease. <i>Blood</i> , 2021, 138, 3723-3723.	1.4	4
9	Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation. <i>Blood</i> , 2021, 138, 1550-1550.	1.4	11
10	Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2021, 138, 2626-2626.	1.4	1
11	Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results. <i>Blood</i> , 2021, 138, 3720-3720.	1.4	1
12	Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. <i>Leukemia and Lymphoma</i> , 2020, 61, 171-175.	1.3	14
13	Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolism. <i>EJHaem</i> , 2020, 1, 448-456.	1.0	3
14	New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. <i>Haematologica</i> , 2020, 105, e355-e357.	3.5	10
15	The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL. <i>Blood</i> , 2020, 136, 28-29.	1.4	6
16	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. <i>Blood</i> , 2020, 136, 42-43.	1.4	11
17	Whole Tumor Histogram Analysis Using DW MRI in Primary Central Nervous System Lymphoma Correlates with Tumor Biomarkers and Outcome. <i>Cancers</i> , 2019, 11, 1506.	3.7	11
18	Dual-Energy X-Ray Absorptiometry Compared to Computed Tomography for Visceral Adiposity Assessment Among Gastrointestinal and Pancreatic Cancer Survivors. <i>Scientific Reports</i> , 2019, 9, 11500.	3.3	5

#	ARTICLE	IF	CITATIONS
19	Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e465-e469.	0.4	7
20	Ibrutinib and Venetoclax for First-Line Treatment of CLL. <i>New England Journal of Medicine</i> , 2019, 380, 2095-2103.	27.0	388
21	Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 574-581.	0.8	9
22	Vascular flow on doppler sonography may not be a valid characteristic to distinguish colloid nodules from papillary thyroid carcinoma even when accounting for nodular size. <i>Gland Surgery</i> , 2019, 8, 461-468.	1.1	6
23	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e51-e61.	0.4	7
24	Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 359-359.	1.4	11
25	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 34-34.	1.4	3
26	Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53. <i>Blood</i> , 2019, 134, 357-357.	1.4	14
27	Liver Calcifications and Calcified Liver Masses: Pattern Recognition Approach on CT. <i>American Journal of Roentgenology</i> , 2018, 211, 76-86.	2.2	29
28	A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. <i>Haematologica</i> , 2018, 103, e416-e418.	3.5	15
29	Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a Comprehensive Cancer Center. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 377-385.	2.1	8
30	Granulomatous dermatitis associated with ipilimumab therapy (ipilimumab associated granulomatous) <i>Tj ETQq0 0 0 rgBT /Overlock 10 T</i>	1.5	17
31	Lynch Syndrome: Genomics Update and Imaging Review. <i>Radiographics</i> , 2018, 38, 483-499.	3.3	21
32	Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Clinical and Imaging Review. <i>Current Problems in Diagnostic Radiology</i> , 2018, 47, 333-339.	1.4	11
33	Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 703-712.	1.7	39
34	A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5883-5894.	7.0	76
35	Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations. <i>Blood</i> , 2018, 132, 695-695.	1.4	11
36	Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 696-696.	1.4	17

#	ARTICLE	IF	CITATIONS
37	Incidental Suspicious Regional Lymph Nodes on Breast Sonography: Is Sampling Necessary?. <i>Current Problems in Diagnostic Radiology</i> , 2017, 46, 100-104.	1.4	1
38	Mammographic breast density is associated with the development of contralateral breast cancer. <i>Cancer</i> , 2017, 123, 1935-1940.	4.1	21
39	Comparative study of computational visual attention models on two-dimensional medical images. <i>Journal of Medical Imaging</i> , 2017, 4, 025503.	1.5	9
40	Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma. <i>Advances in Radiation Oncology</i> , 2017, 2, 363-369.	1.2	9
41	Polytetrafluoroethylene or Acellular Dermal Matrix for Diaphragmatic Reconstruction?. <i>Annals of Thoracic Surgery</i> , 2017, 103, 1710-1714.	1.3	8
42	Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual PET-positive disease be cured with radiotherapy alone?. <i>British Journal of Haematology</i> , 2017, 179, 488-496.	2.5	9
43	The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma. <i>Urology</i> , 2017, 108, 114-121.	1.0	11
44	Performance of 4T score and heparin-platelet factor 4 antibody in the diagnosis of heparin-induced thrombocytopenia (HIT) in cancer. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 261-266.	2.1	5
45	Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 333-338.	0.8	10
46	Dorsal column myelopathy after intrathecal chemotherapy for leukemia. <i>American Journal of Hematology</i> , 2017, 92, 155-160.	4.1	30
47	Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. <i>JCI Insight</i> , 2017, 2, e89904.	5.0	78
48	Outcomes of Venous Thromboembolism (VTE) Treatment in Thrombocytopenic Leukemic Patients. <i>Blood</i> , 2016, 128, 4964-4964.	1.4	0
49	Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 2416-2423.	1.5	125
50	An Update of Practical CT Adrenal Imaging: What Physicians Need to Know. <i>Current Radiology Reports</i> , 2015, 3, 1.	1.4	5
51	Tumor Thrombus as a Rare Presentation of Lymphoma: A Case Series of 14 Patients. <i>American Journal of Roentgenology</i> , 2015, 204, W398-W404.	2.2	12
52	High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial. <i>Blood</i> , 2015, 126, 3987-3987.	1.4	6
53	High prevalence of recurrent thrombosis in subsets of cancer patients with isolated gonadal vein thrombosis: A single center retrospective study. <i>Thrombosis Research</i> , 2014, 133, 154-157.	1.7	8
54	Stereoscopic Interpretation of Low-Dose Breast Tomosynthesis Projection Images. <i>Journal of Digital Imaging</i> , 2014, 27, 248-254.	2.9	7

#	ARTICLE	IF	CITATIONS
55	Aggressive Angiomyxomas: A Comprehensive Imaging Review With Clinical and Histopathologic Correlation. American Journal of Roentgenology, 2014, 202, 1171-1178.	2.2	42
56	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncology, The, 2014, 15, 1090-1099.	10.7	315
57	Imaging of Chemotherapy-related Iatrogenic Abdominal and Pelvic Conditions. Radiologic Clinics of North America, 2014, 52, 1029-1040.	1.8	5
58	Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 307-313.	7.3	21
59	Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood, 2014, 123, 4132-4135.	1.4	86
60	Complications of oncologic therapy in the abdomen and pelvis: a review. Abdominal Imaging, 2013, 38, 1-21.	2.0	20
61	Beyond the GIST: Mesenchymal Tumors of the Stomach. Radiographics, 2013, 33, 1673-1690.	3.3	116
62	Kinetics Of Chronic Lymphocytic Leukemia Cells In Tissues and Blood During Therapy With The BTK Inhibitor Ibrutinib. Blood, 2013, 122, 4166-4166.	1.4	1